Caitlin Rausch

32PUBLICATIONS
69CO-AUTHORS
Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Medical virologyHaematology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (32)

|Aug 20, 2026
Evaluation of hypomethylating agents with or without venetoclax in patients with accelerated phase and blast phase myeloproliferative neoplasms: a HERO consortium study.

|Jun 27, 2026
Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia.

|Apr 26, 2026
Cladribine With Low-Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia.

|Apr 17, 2025
Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients.

Christophe Willekens, Alexandre Bazinet, Samy Chraibi

|Apr 07, 2025
Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single-center, single-arm, phase 2 trial.

Hannah Goulart, Hagop Kantarjian, Gautam Borthakur

|Mar 26, 2025
Multicenter Retrospective Evaluation of Treatment for High-Risk Acute Promyelocytic Leukemia: Real-World Outcomes From the HERO Consortium.

Lydia L Benitez, Kayleigh R Marx, Caitlin R Rausch

Pageof 6

Frequent Collaborators

21 joint publications

Tapan M Kadia

20 joint publications

Hagop M Kantarjian

17 joint publications

Courtney DiNardo

15 joint publications

Naval G Daver